The biggest approval decision in October will involve Novartis’s eye asset Beovu, while Biogen and Alkermes face a key verdict in MS.
Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?
Deals were a major driver of mid-cap share movement in the first quarter, but pipeline progress and misfires played their parts too.
Pharma and biotech takeover activity slumps to a five-year low in 2017.
No slowdown at the FDA, as regulator remains on track to approve at least 43 new drugs this year.